Mirazid (Commiphora molmol) in treatment of human heterophyiasis.
A total of 3278 patients attended Mansoura University Hospitals' Clinics with gastro-intestinal troubles suggesting parasitosis were examined by direct smear and by Kato-Katz methods for parasites especially Heterophyes heterophyes. Fifty clinically and parasitologically proved pure heterophyiasis patients were given Mirazid as two capsules for 9 successive days on an empty stomach an hour before breakfast. All the cases were subjected to history taking and clinical examination before treatment and were followed-up for four weeks post-treatment. There was an overt clinical and parasitological improvement. A total of 47 out of 50 (94%) were cured. Another course was given to the three patients who were still positive, but only two of them were cured (66.7%). The overall cure rate was 49/50 (98%) and none had any side effect. The history and treatment of this zoonotic parasite was critically discussed.
Massoud
Ahmad M
AM
Department of Tropical Medicine, Faculty of Medicine, AI-Azhar University, Cairo, Egypt.
El-Shazly
Atef M
AM
Morsy
Tosson A
TA
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000818:Animals; D000980:Antiplatyhelmintic Agents / Q000627:therapeutic use*; D002648:Child; D029744:Commiphora / Q000737:chemistry*; D005260:Female; D006578:Heterophyidae / Q000187:drug effects* / Q000254:growth & development; D006801:Humans; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use*; D016896:Treatment Outcome; D014201:Trematode Infections / Q000188:drug therapy*
D000980:Antiplatyhelmintic Agents; D010936:Plant Extracts